Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EffRx receives FDA approval for osteoporosis drug
The company expects to launch the product in the US in the third quarter of 2012. BINOSTO is a treatment option for those patients who have difficulty with
The company expects to launch the product in the US in the third quarter of 2012. BINOSTO is a treatment option for those patients who have difficulty with
Mobile Intelligence solution allows Gedeon Richter Spain to exercise superior control over spending and commercial operations. The solution also provides advanced profiling, planning and targeting tools which empower
MedPodium Nutra-Apps capsules are small, sealed and come in one-and-done dosing to promote personal health and well being. Under the partnership, NPI distributes Nutra-Apps products to retail and
The company will use Mobile Intelligence for its primary care, specialty, key account management and over-the-counter commercial teams. Mobile Intelligence features an intuitive Graphic User Interface (GUI) for
The DSIMS software is a repository, unified data model, viewer and analytical tool behind the FDA’s Nonclinical Information Management Solution (NIMS). FDA reviewers will use NIMS to view,
INyDIA will provide My5-FU test kits to laboratories, enabling oncologists to individualize 5-FU dosing to optimize therapeutic efficacy and reduce toxicity for their patients. My5-FU measures levels of
The collaboration will investigate and evaluate the implementation of a pharmacogenetic program in a community pharmacy. The study involves a protocol jointly developed by Kerr Drug and UNC
HQK-1001 is an orally administered Short Chain Fatty Acid Derivative (SCFAD), and has been evaluated in a number of clinical trials in sickle cell disease and beta thalassemia.
The Mevopur colorants block UV, thereby helping to protect UV sensitive pharmaceutical products. The pre-evaluated Mevopur colourants help reduce customers’ development times and costs, and minimize risk of
The study will evaluate the oral bioavailability of RX-3117 in humans. The company will continue the enrollment through the first half of 2012 and expects to release the